𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Molecular genetics of familial hypercholesterolemia in Spain: Ten novel LDLR mutations and population analysis

✍ Scribed by Ana B. García-García; José T. Real; Oscar Puig; Elvira Cebolla; Pablo Marín-García; Jose I. Martínez Ferrandis; Magdalena García-Sogo; Miguel Civera; Juan F. Ascaso; Rafael Carmena; M. Eugenia Armengod; F. Javier Chaves

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
40 KB
Volume
18
Category
Article
ISSN
1059-7794

No coin nor oath required. For personal study only.

✦ Synopsis

Communicated by Mark H. Paalman

Mutations underlying FH in Spain are largely unknown because only a few and limited surveys have been carried out on Spanish FH patients up to now. To gain information on this issue, we have analysed a group of 113 unrelated Spanish FH patients from an eastern area of Spain (Valencian Community). We have screened the LDLR gene by Southern blot and PCR-SSCP analysis to detect large rearrangements and small mutations, respectively. In addition, we have screened the Apo B gene for mutations known to cause FDB by PCR-SSCP analysis. We have identified a total of 47 different mutations in the LDLR gene (5 large rearrangements, and 42 small mutations, which were characterized by DNA sequencing), 19 of which have not been described in other populations (Valencia-1 to -4, 112insA, P160R, 790DelATGA, 920insTCAG, G642E, and the ten novel mutations E246A, 884delT, I289T, S305F, Q328X, Y354C, I603del, 2312-3C>A, V779M, and N804K). Three of these mutations (15%) were present in more than 1 proband, being mutation 112insA the most prevalent (frequency ∼ ∼ 8%) in our sample. The Apo B gene R3500Q mutation was found in only one patient and no underlying defect was found in about 27% of patients. Our data support the notion that Spaniards represent a heterogeneous population with its own spectrum of LDLR gene mutations and that, in our population, FDB has a lower frequency or a milder expression than in central Europe countries.

📜 SIMILAR VOLUMES

Molecular characterization of familial h
Molecular characterization of familial hypercholesterolemia in Spain: Identification of 39 novel and 77 recurrent mutations in LDLR
✍ Pilar Mozas; Sergio Castillo; Diego Tejedor; Gilberto Reyes; Rodrigo Alonso; Mig 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

Mutations in the low-density lipoprotein receptor (LDLR) gene cause familial hypercholesterolemia (FH), an autosomal dominant inherited disorder associated with an increased risk of premature atherosclerosis. The aim of this study was to characterize the LDLR mutations in a group of 476 apparently n

Molecular basis of familial hypercholest
Molecular basis of familial hypercholesterolemia in Brazil: Identification of seven novel LDLR gene mutations
✍ Luis A. Salazar; Mario H. Hirata; Selma A. Cavalli; Edna R. Nakandakare; Neusa F 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB 👁 1 views

## Communicated by Mark H. Paalman Low-density lipoprotein receptor (LDLR) gene mutations cause familial hypercholesterolemia (FH), one of the most common single gene disorders. The spectrum of LDLR mutations in Brazil is not known. The aim of this study was the characterization of LDLR mutations

Functional analysis of LDLR promoter and
Functional analysis of LDLR promoter and 5′ UTR mutations in subjects with clinical diagnosis of familial hypercholesterolemia
✍ Isabel De Castro-Orós; Sandra Pampín; Alfonso Bolado-Carrancio; Aguirre De Cubas 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 252 KB 👁 1 views

Familial hypercholesterolemia (FH) is a dominant disorder due to mutations in the LDLR gene. Several mutations in the LDLR promoter are associated with FH. Screening of 3,705 Spanish FH patients identified 10 variants in the promoter and 5 0 UTR. Here, we analyse the functionality of six newly ident

The molecular basis of familial hypercho
The molecular basis of familial hypercholesterolemia in Lebanon: Spectrum of LDLR mutations and role of PCSK9 as a modifier gene
✍ Marianne Abifadel; Jean-Pierre Rabès; Sélim Jambart; Georges Halaby; Marie-Hélèn 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 1 views

Autosomal dominant hypercholesterolemia (ADH), a major risk for coronary heart disease, is associated with mutations in the genes encoding the low-density lipoproteins receptor (LDLR), its ligand apolipoprotein B (APOB) or PCSK9 (Proprotein Convertase Subtilin Kexin 9). Familial hypercholesterolemia

Molecular analysis in Fabry disease in S
Molecular analysis in Fabry disease in Spain: Fifteen novel GLA mutations and identification of a homozygous female
✍ Adriana Rodríguez-Marí; M. José Coll; Amparo Chabás 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB 👁 1 views

Fabry disease, an X -linked inborn error of glycosphingolipid catabolism, results from mutations in the α-galactosidase A gene (GLA). Here we report molecular studies in 22 unrelated Spanish patients with Fabry disease ( 20 males and two females). Fifteen novel mutations were identified. In addition

Mutation analysis in 36 unrelated Spanis
Mutation analysis in 36 unrelated Spanish subjects with familial hypercholesterolemia: Identification of 3 novel mutations in the LDL receptor gene
✍ Pilar Mozas; Ana Cenarro; Fernando Civeira; Sergio Castillo; Emilio Ros; Miguel 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 39 KB 👁 2 views

We used the single strand conformation polymorphism (SSCP) method to investigate 36 apparently unrelated Spanish patients with familial hypercholesterolemia (FH) for mutations in the promoter region and the 18 exons and their flanking intron sequences of the low density lipoprotein receptor (LDLR) g